European Molecular Imaging Markets to Be Driven by Clinical Advances

This mounting user base is expected to increase revenues for the European molecular imaging market.

New market research from Frost & Sullivan (Palo Alto, CA, USA), an international growth consultancy company, revealed that the markets earned revenues of USD 276.0 million in 2011 and estimates this to reach USD 388.4 million in 2018. The analysis encompasses single photon emission computed tomography (SPECT), positron emission tomography (PET), single and planar segments.

“The discovery of novel radiotracers is expanding the use of molecular imaging diagnostics to newer clinical applications,” noted Frost & Sullivan research analyst Kaavya Karunanithi. “In addition to the traditional fields of oncology and cardiology, neurology as well as infectious and inflammatory disease segments are increasingly leveraging molecular imaging techniques with radiotracers, thus widening the application base.”

Market penetration is also being driven by the prevalence and mindfulness of cancer. Procedural volumes of various cancer screening technologies, including PET and PET/CT, are rising. Additionally, the ability to simplify customized treatment is encouraging the use of molecular imaging technologies. Moreover, technologic developments continue to drive growth in the molecular imaging markets. For instance, hybrids such as the recently introduced PET/magnetic resonance imaging (MRI) provide higher specificities than currently available PET/computed tomography (CT).

“In the long run, optical modalities and tri-modality systems, with the ability to cater to a wider clinical application portfolio, will dominate,” added Ms. Kaavya. “Such technically advanced offerings boost market prospects, even while addressing the demand for personalized medicine.”

With these rapid technologic developments, there is a critical need for skilled technicians and physicians to effectively acquire and decipher images. This is an important challenge, which needs to be addressed. “Market participants must stay abreast of the high degree of technologic change,” advised Ms. Kaavya. “They will need to provide innovative, accurate, and reliable solutions that facilitate personalized medical care.”

Related Links:
Frost & Sullivan